Haemonetics Co. (NYSE:HAE) Shares Bought by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA increased its position in Haemonetics Co. (NYSE:HAE) by 16.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,963 shares of the medical instruments supplier’s stock after buying an additional 979 shares during the period. Pictet Asset Management Holding SA’s holdings in Haemonetics were worth $544,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of HAE. Whittier Trust Co. acquired a new position in Haemonetics in the 4th quarter valued at $62,000. Parkside Financial Bank & Trust increased its stake in Haemonetics by 25.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. AlphaQuest LLC lifted its position in Haemonetics by 36,520.0% during the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock worth $143,000 after buying an additional 1,826 shares during the period. KBC Group NV boosted its stake in Haemonetics by 54.6% in the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after buying an additional 712 shares during the last quarter. Finally, HighTower Advisors LLC grew its holdings in Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock valued at $262,000 after buying an additional 244 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Down 5.2 %

Shares of Haemonetics stock opened at $55.89 on Wednesday. Haemonetics Co. has a 1-year low of $55.42 and a 1-year high of $97.97. The company has a market capitalization of $2.81 billion, a PE ratio of 22.00, a P/E/G ratio of 1.11 and a beta of 0.41. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The business has a 50-day moving average of $64.25 and a 200-day moving average of $73.87.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.20 by ($0.01). Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. As a group, equities analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Bank of America cut shares of Haemonetics from a “neutral” rating to an “underperform” rating and lowered their price objective for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research cut their price objective on Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Raymond James reaffirmed a “strong-buy” rating and set a $115.00 price target (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Finally, Needham & Company LLC dropped their price objective on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.22.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.